Therapeutic Effects of Specialized Pro-Resolving Lipids Mediators on Cardiac Fibrosis via NRF2 Activation

Area of Science:

• Cardiovascular Research
• Molecular Biology
• Lipid Metabolism

Background:

• Heart disease is a leading global cause of mortality.
• Cardiac fibrosis significantly contributes to myocardial infarction and heart failure.
• Oxidative stress is a primary driver of cardiac fibrosis.

Purpose of the Study:

• To review the activation of nuclear factor erythropoietin 2 related factor 2 (NRF2) by specific polyunsaturated lipids.
• To explore the role of docosahexanoic acid (DHA), eicosapentaenoic acid (EPA), and specialized pro-resolving lipid mediators (SPMs) in NRF2 activation.
• To discuss the impact of these lipid mediators on cardiac fibrosis through NRF2 modulation.

Main Methods:

• Literature review focusing on NRF2 activation pathways.
• Analysis of studies investigating the effects of DHA, EPA, and SPMs on oxidative stress.
• Examination of research linking NRF2 activity to the suppression of cardiac fibrosis.

Main Results:

• DHA, EPA, and SPMs are identified as activators of the NRF2 pathway.
• NRF2 activation by these lipids demonstrates a protective effect against oxidative stress.
• Evidence suggests that NRF2-mediated mechanisms can mitigate cardiac fibrosis.

Conclusions:

• Docosahexanoic acid (DHA), eicosapentaenoic acid (EPA), and specialized pro-resolving lipid mediators (SPMs) represent a promising therapeutic avenue for managing cardiac fibrosis.
• Targeting the NRF2 pathway with these lipid compounds offers a potential strategy to combat heart disease progression.
• Further research into NRF2 activation by omega-3 fatty acids and SPMs is warranted for cardiovascular health.